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LPS induces major changes in the extracellular proteotytic balance in
the murine kidney. Recent investigations have shown that in the murine
kidney urokinase (uPA) and tissue-type plasminogen activator (tPA) are
synthesized and released in urine by tubular epithelial cells, raising the
possibility that plasminogen activators (PAs) may be involved in the
maintenance of patency and fluidity in renal tubules. To further
investigate the contribution of the PA system in renal pathology, we
have determined the effects of LPS on the renal production of PM: we
localized PA-catalyzed proteolysis by zymographic analysis of tissue
sections and studied the accumulation of mRNAs for PAs and their
inhibitors (PAl-i and PAI-2) by in situ hybridization. Both a single and
two injections of LPS induced a dramatic reduction in urinary and renal
uPA enzymatic activity; this decrease in catalytic activity was attrib-
utable to a reduction in uPA mRNA levels in both proximal and distal
tubules. By contrast, we noticed a marked increase of tPA mRNA
content in glomerular cells which was not accompanied by a concom-
itant increase in tPA-mediated proteolytic activity. In addition, a major
up-regulation in PAL-i mRNA levels was observed throughout the
kidney, while PAI-2 mRNA was not detectable in the kidneys of control
or LPS-injected animals. Our investigations document the profound
alterations of the PA/PAl balance in renal tissue following in vivo LPS
administration. They suggest that imbalanced extracellular proteolysis
might participate in the alterations of kidney function observed in septic
shock.
Two types of plasminogen activators (PAs) have been iden-
tified in mammals: urokinase (uPA) and tissue-type plasmino-
gen activator (tPA). They are serine proteases, produced by
distinct genes, which catalyze the conversion of plasminogen
into plasmin, a protease capable of degrading directly or indi-
rectly most extracellular proteins [I]. PAs are synthesized by a
wide variety of cell types and secreted in the extracellular
compartment where they can interact with numerous mole-
cules, such as specific cell surface receptors, physiological
inhibitors (PAls) and extracellular matrix (ECM) components
[2]. Experimental evidence suggests that interactions between
secreted PAs and their extracellular ligands concur to focus
plasmin-mediated proteolysis to defined regions of the pericel-
lular milieu, providing PA-producing cells with efficient means
to degrade extracellular constituents in a spatially restricted
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fashion [1]. Indeed, uPA, which is produced by cell types
endowed with invasive properties, has generally been consid-
ered to play a pivotal role in controlling the ECM degradation
that is needed for cell migration and tissue invasion [3], while
tPA, which is mainly synthesized by endothelial cells, is
thought to participate in fibrinolysis [4]. However, uPA is also
produced by cells that are not involved in cell migration and
tissue remodeling, suggesting that the enzyme may fulfill a
larger spectrum of functions [5]. Epithelial cells lining the
straight portions of both proximal and distal kidney tubules
produce and secrete uPA in urine; similarly, tPA is synthesized
by epithelial cells of collecting ducts and is also found, though
in minimal amounts, in urine [6]. These observations raise the
possibility that PA-catalyzed extracellular proteolysis may not
only participate in ECM degradation or fibrinolysis, but also
exert other functions, related to the role attributed to tPA in the
vascular bed, for instance, PAs could help insure the mainte-
nance of tubular patency.
To explore the potential role of PA-catalyzed proteolysis in
renal physiology and pathology, we have studied the effects of
LPS administration on the renal munne PA/PAl system in vivo.
We describe here the differential modulations in uPA, tPA,
PAI-l and PAI-2 gene expression that occur shortly after i.p.
injection of LPS.
Methods
Material
All experiments were performed on two- to six-month-old
adult male and female B6 mice maintained on a standard mouse
diet and allowed free access to water. Animals were injected
i.p. with a single 100 pi dose of endotoxin (Escherichia coli
lipopolysaccharide), at a concentration of 1 mg/mI of LPS
diluted in isotonic saline solution. Animals were sacrificed 3, 8
and 48 hours post-injection. For each time point, three animals
were studied. Alternatively, a first injection of 100 p1 LPS was
followed 24 hours later by a second 25 p1 injection, three mice
being sacrificed eight hours later and two mice 18 hours
thereafter.
At the times specified, kidney tissues were prepared as
described [6]. Blood was obtained by aortic section, collected in
5 U/mI heparin (Liquemine, Roche, Switzerland), and centri-
fuged; plasma was extracted and stored at —70°C. Excreted
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urine was obtained from urethral discharge after animal han-
dling. Pelvic urine was collected through the renal pelvis of
anesthetized animals with a glass pipette after ureteral ligature.
Histological studies
Samples of kidney tissues were fixed in 10% formalin and
paraffin-embedded. Seven micrometer thick sections were
stained with periodic acid Schiff (PAS) for light microscopy.
Chemical analyses
Plasma urea and creatinine were determined by kinetic methods
[7, 8]. Proteinuna was determined by the Lowry method [9].
Enzymatic analyses
Zymographies of plasma and urine specimens were per-
formed after SDS-PAGE electrophoresis as described [101.
Zymographies on cryostat tissue sections were performed as
described [6]: the overlay mixture was prepared with 40 gIml
plasminogen, to which were added, when indicated, 1 m
amiloride or 1 mri amiloride and 0.2 mglml of specific anti-tPA
antibodies (anti-human uterine tPA, American Diagnostica).
Zymograms were allowed to develop for 30 minutes to six hours
at 37°C. Photographs were taken using dark-ground illumina-
tion.
mRNA analyses
Total RNAs were extracted as described [11]. RNAs were
denatured with glyoxal, fractionated on 1.2% agarose gels, and
transferred overnight onto Hybond-N membranes (Amersham).
Prehybridizations, hybridizations and posthybridization washes
were performed as previously described [12]. The uPA anti-
sense probe was prepared from pSP64-MU, containing the
658-bp Pst I-Hind III fragment of the mouse uPA cDNA clone
pBDB29 [13]. The tPA anti-sense probe was prepared from
SP64-MT3, containing the 726-bp Pvu Il-Spe I fragment of the
mouse tPA cDNA clone pUC9-A33 [14]. The PAl-i anti-sense
probe was prepared from pRlO6, containing the 350-bp Pst
1-Apa I fragment of the rat PA!-! eDNA clone [15]. The PAI-2
anti-sense probe was prepared from pDB5O91, containing the
353-bp Pvu IT-B stY I fragment of the mouse PAI-2 cDNA clone
[16]. Probes were transcribed in vitro in the presence of 12.5 xM
of a[32P]-labeled UTP (uridine 5'-triphosphate, 400 Ci/mmol;
Amersham International, Amersham, UK) or with 30 pM [3H]-
labeled UTP and 30 M [3H]-labeled CTP (cytidine 5'-triphos-
phate, 40 and 20 Ci/mmol, respectively; Amersham Internation-
al). 3H-labeled probes were reduced to an average size of 50 to
100 nt by mild alkaline hydrolysis as previously described [17].
Quantification of Northern blots was by phosphor imager
analysis (Image Quant Software FAST SCAN, Molecular Dy-
namics Ltd, Kemsing, UK).
In situ hybridizations were performed as described [6].
Briefly, 5 to 6 pin cryostat kidney tissue sections were mounted
on poly-L-lysine (Sigma Chemical Co., St. Louis, Missouri,
USA)-coated microscope slides, fixed in 4% glutaraldehyde in
PBS for one minute, rinsed in PBS, and stored in 70% ethanol
at 4°C. Prehybridizations, hybridizations and posthybridization
washes were performed as previously described [17]. Two
times 106 cpm of 32P-labeled cRNAs or 0.6 x 106 cpm of
3H-labeled cRNAs were applied to each section in 30 d of a
hybridization mixture as described [17]. After graded ethanol
dehydration, sections hybridized to 32P-labeled cRNAs were
directly exposed to X-ray films (SB5; Eastman Kodak Co.,
Rochester, New York, USA) at room temperature and the films
developed after two to seven days. Sections hybridized to
3H-labeled cRNAs were immersed in NTB-2 emulsion (East-
man Kodak), diluted 1:1 in deionized water; after seven months
exposure, slides were developed in Kodak D-19 developer,
fixed in 30% Na thiosulfate and counterstained in methylene
blue.
Results
To analyze the effects of LPS on the renal PAJPAI balance,
we injected LPS into normal mice and studied four of the major
protagonists of the system, namely uPA, tPA, PAl-i and PAI-2,
using mice injected with normal saline as controls. We injected
either a single (100 g) or two LPS doses (100 g followed at 24
hours by 25 g) i.p. LPS injection induced a state of prostration
which started after two hours and lasted until sacrifice.
Blood urea was significantly increased at three and eight
hours after the single LPS injection (respectively 18.0 2.43
mmol/liter and 30.23 3.93 mmoi/liter vs. 9.37 1.93 mmol/
liter and 8.33 2.0 mmol/liter for the controls; for both
measures, P < 0.01) and increased further at 8 and 18 hours
after the second dose (respectively 41.5 7.4 mmollliter and 65
mmollliter vs. 8.95 0.7 mmollliter and 9.06 0.1 mmollliter
for the controls; for both measures, P < 0.01). There was no
increase in plasma creatinine after one LPS injection. Creatine-
mia increased to 86 moIIliter only in one animal 18 hours after
the second dose of LPS. There was no increase in proteinuria.
Histological analysis of specimens taken at 18 hours after the
second LPS injection revealed tubular alterations (Fig. 1):
dilation of a majority of tubules localized exclusively in the
cortex (identification of the altered segments, proximal and/or
distal, was not possible); flattening of the epithelial cells and
desquamated debris in the intratubular lumen, however, with-
out typical cylinders were observed. The other segments, that
is, straight parts of proximal and distal tubules, the Henle's
loops and the collecting tubes were normal. We did not detect
any glomerular, vascular or interstitial lesions. The morpholog-
ical appearance of specimens from animals sacrificed 3, 8 and 48
hours after one injection, or eight hours after two injections,
was normal.
Urinary plasminogen activators
SDS-PAGE zymography was performed on bladder and
pelvic urine samples collected at eight hours after a single LPS
injection (Fig. 2). Three zones of caseinolysis were apparent,
two of which corresponded to uPA (48 kD) and its 28 kD
degradation product. These two zones were inhibited by
amiloride which is a known selective inhibitor of uPA catalytic
activity [18]. Urines from both sites contained much less uPA
than urines from control animals. By contrast, the third zone of
caseinolysis (72 kD), which corresponded to tPA activity, was
moderately higher in the urines of LPS-treated mice. In bladder
urine collected at eight hours after the second LPS injection,
uPA-induced caseinolysis was undetectable (Fig. 3). In the
absence of plasminogen no caseinolysis was observed, confirm-
ing that the enzymatic activities were due to PAs (data not
shown).
Free PAT was not detected in normal urines as demonstrated
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Fig. 1. Histological analysis of a kidney
tissue section 18 hours after two LPS
injections. Light micrograph (x40). Many
tubules are dilated and their epithelium is
flattened. Desquamated debris are seen in the
tubular lumen. The injured tubules are
localized in the cortex; it is not possible to
determine whether they are of proximal or
distal nature. The glomerulus and the
interstitium appear normal.
FIg. 2. Lymograpluc analysis of I-'As in urine after one LJ-'., injection, tine milliliter oi rresn peivic LI') ana excretea Lu) urines Irom one control
(C) and one LPS (LPS) injected animal, collected at 8 hours after one LPS injection, were analyzed by SDS-PAGE and zymography, in the absence
(A—) or in the presence (A+) of 1 msi amiloride in the substrate, which selectively inhibits uPA [18]. Photographs were taken after the indicated
time (I hr 30 mm, 5 hr 30 miii and 24 hr) of incubation of the zymogram at 37°C. The 72 kD lytic zone corresponds to tPA, the 48 kD to uPA and
the 28 kli to low molecular mass uPA. uPA-catalyzed caseinolysis is detectable in the pelvic and bladder urine of the control mouse after 1 hr 30
mm of incubation of the zymogram but only after 5 hr 30 miii for the LPS animal. tPA-catalyzed caseinolysis is apparent in the pelvic urine of the
LPS-injected mouse after 5 hr 30 miii of incubation of the zymogram, but only after 24 hours for the control animal,
by reverse zymography (data not shown), and remained unde-
tectable after the LPS injection. In addition urines of control
and LPS-injected mice did not contain PA/PAl complexes,
except for one sample of pelvic urine which had been contam-
inated with blood (not shown); the complexes in this sample
were probably due to PAls present in blood, which reacted with
urinary tPA since the lysis was not inhibited by amiloride.
Renal enzymatic activities
To determine whether the changes in enzymatic activities
observed in urine could be attributed to a reduced production at
the renal sites of PAs' synthesis, histological zymograms were
performed on kidney cryostat tissue sections. uPA catalyzed-
proteolysis over the outer medulla, a region known to be a
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Fig. 3. Zymographic analysis of uPA in urine
after two LPS injections. One milliliter of
fresh bladder urine from two control (C) and
three LPS injected (LPS) animals were
analyzed before any injection (before) and 8
hours after the second injection (after) by
SDS-PAGE and zymography, in the absence
(A—) or in the presence (A+) of 1 mM
amiloride in the substrate. Photographs were
taken after 7 hours of incubation of the
zymogram at 37°C. Murine uPA standard (St).
The 48 kD lytic zone corresponds to uPA and
the 28 kD to low-molecular-mass uPA. After
the second injection, no uPA-catalyzed
caseinolysis is detectable in urine of the LPS-
injected animals.
Fig. 4. Localization of u-PA mRNA and
enzymatic activity on kidney tissue sections
after one LPS injection. Cryostat tissue
sections of control (—LPS) and LPS-injected
(+LPS) mice sacrificed 8 hours after injection
were analyzed. (A) and (D) show the regional
localization of uPA mRNA by in situ
hybridization to a 32P-Iabeled cRNA probe:
photographs were taken after 48 hours
exposure at room temperature. (B), (C), (B)
and (F) show regional localization of uPA
enzymatic activity by histological
zymographies in the absence (B and E) and in
the presence (C and F) of 1 m of amiloride
(B and E) and in the presence (C and F) of I
m of amiloride which selectively inhibits
uPA activity [18]. Photographs were taken
after 1 hr 30 mm of incubation of the
zymogram at 37°C. uPA mRNA levels and
uPA-catalyzed caseinolysis are decreased in
the outer medula of LPS-injected mice.
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Fig. 5. Localization of tPA mRNA and
enzymatic activity on kidney sections after
one LPS injection. Cryostat tissue sections of
control (—LPS) and LPS-injected (+LPS)
mice sacrificed 8 hours after injection were
analyzed. (A) and (D) show the regional
localization of tPA mRNA by in situ
hybridizations to a 32P-labeled cRNA probe:
photographs were taken after 48 hours
exposure at room temperature. (B), (C), (E)
and (F) show regional localization of tPA
enzymatic activity by histological
zymographies in the presence of 1 m of
amiloride (B and E) and in the presence of I
mM of amiloride and 0.2 mg/mI anti-tPA
antibodies (C and F): photographs were taken
after 5 hr 30 mm of incubation of the
zymogram at 37°C. tPA mRNA levels are
increased in the cortex of the LPS-injected
mice, but tPA-catalyzed caseinolysis is not
modified.
major site of uPA activity in the normal kidney, was dramati-
cally decreased on kidney sections from LPS-injected mice
(Fig. 4 B, E). Prolonged incubation of the zymograms in the
presence of amiloride, which inhibits uPA catalytic activity and
therefore allows the identification of tPA, revealed zones of
proteolysis over glomerular structures and over the papilla,
which were of similar intensity in LPS-treated animals and in
controls (Fig. 5 B, E). Corresponding sections were incubated
in the presence of anti-tPA antibodies in the substrate which
prevented caseinolysis over glomerular and papillary structures
(Fig. 5 C, F), confirming that tPA was responsible for the
observed proteolytic activity over these regions. Similar
changes were observed after one and two LPS injections.
PAs' and PAls' mRNAs
To determine whether the modifications in PAs' enzymatic
activities could be accounted for by modulations in PAs' and
PAls' mRNA levels, we analyzed total RNAs extracted from
LPS-treated and control kidneys. As shown in Figure 6, the
amount of uPA mRNA decreased at three and eight hours after
one LPS injection, while tPA mRNA levels increased at three
hours to reach a maximum at eight hours. PA!-! mRNA levels
increased also, but were maximal already at three hours. The
amounts of these three mRNAs returned towards baseline
values at 48 hours. The changes observed on Northern blots
were quantified by phosphor imager: the decrease in uPA
mRNA was approximately two- to threefold, and the increase in
tPA mRNA was of a similar magnitude. The modifications in
the basal expression of PA!-! mRNA were more pronounced,
since the increase was 20-fold at three hours. No PAI-2 mRNA
was detected in kidneys from control or LPS-treated animals
(data not shown).
Localization of PAs' and PAls' mRNAs.
The sites of PAs/PAIs mRNAs' accumulation were localized
at the regional level by hybridizing kidney tissue sections to
32P-labeled cRNA probes. uPA mRNA levels were decreased in
the outer medulla after LPS injection when compared to con-
trols (Fig. 4 A, D). tPA mRNA levels were increased in
glomerular structures, while the accumulation of tPA mRNA in
the papilla did not differ dramatically between LPS-injected and
control animals (Fig. 5 A, D). Similar modulations were ob-
served after one and two LPS injections. Thus, LPS injection
did not change the sites of accumulation of uPA or tPA
mRNAs, but affected their abundance at the sites at which they
are present in the normal kidney. The reduction of uPA mRNA
levels, localized with a 3H-labeled cRNA in straight portions of
proximal and distal tubules (data not shown), matched the
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Fig. 6. Northern blot analysis of uPA, tPA and PAl-i mRNAs in total RNA extracted from murine kidneys. Mice injected with one dose of NaC1
or LPS were sacrificed after 3, 8 or 48 hours post-injection. Three animals were studied for each time point. Five micrograms of total kidney RNA
from each mouse were analyzed using uPA, tPA and PAl-i cRNA probes. The membranes were exposed for 48 hours at —8OC, between
intensifying screens. Even loading and the integrity of RNAs were verified by staining membranes after transfer with methylene blue. uPA mRNA
levels decreased at 3 and 8 hours after LPS injection. tPA mRNA level increased at 3 hours and reached a maximum at 8 hours after LPS injection.
PAl-I mRNA level is maximal already at 3 hours.
reduced uPA enzymatic activity observed. In contrast, the
relative increase in tPA mRNA content in glomerular structures
of LPS-treated animals was not accompanied by an increase in
enzymatic activity on histological zymographies, when com-
pared to controls.
PAl-i mRNA accumulation in LPS-injected animals was
observed throughout the kidney, with a speckled reinforcement
in the cortex suggesting glomerular localization (Fig. 7). As
expected from total RNA analysis, PA!-! mRNA was not
detected at the macroscopic level in control animals, even after
prolonged exposure of the tissue sections.
Discussion
The repercussions of septicemia on kidney structure and
function have been recognized for many decades: septic shock
is known to induce a spectrum of vascular, tubular and inter-
stitial damages, which are thought to contribute cooperatively
to renal failure [19—23]. However, the mechanisms underlying
these injuries are poorly understood. Abundant evidence sup-
ports the participation of PAs as mediators of extracellular
proteolysis in renal biology. uPA, originally identified in human
urine [24], is found in the urine of numerous mammalian species
[25, 26]. In vitro studies have documented the production of
uPA and tPA by renal cells, both glomerular and tubular
[27—33]. Alterations in the kidney PA/plasmin system have been
demonstrated in a variety of experimental and clinical renal
disorders [34—36], and may be involved in the abnormal fibrin
deposition that is a common feature of diverse renal patholo-
gies. More recent investigations have shown that in the murine
kidney PAs are predominantly produced and released in urine
by tubular epithelial cells, raising the possibility that PAs may
prevent inappropriate protein deposition in renal tubules [6]. To
determine whether renal PAs may represent molecular targets
of systemic infections, we explored the effects of LPS admin-
istration on the PA/plasmin system in the munne kidney.
We have found that LPS administration induces rapid and
marked alterations in the expression of three components of the
renal PA/plasmin system. LPS caused a dramatic reduction in
urinary uPA enzymatic activity that resulted from reduced
enzyme production by epithelial cells lining proximal and distal
tubules. This decrease in uPA production was correlated with a
decrease in uPA mRNA abundance, suggesting that it resulted
-LPS +LPS
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Fig. 7. Localization of PAl-i mRNA on
kidney sections after one LPS injection.
Cryostat tissue sections of control (—LPS)
and LPS-injected (+LPS) mice sacrificed 3
hours (A and C) and 8 hours (B and D) after
injection are analyzed by in situ hybridization
with a 32P-labeled cRNA probe. Photographs
were taken after 48 hours exposure at room
temperature. PAl-i mRNA levels are
increased, particularly at 3 hours after LPS
injection, throughout the kidney, with a
speckled reinforcement in the cortex. PA!-!
mRNA is not detectable in control animals.
from decreased transcription of the uPA gene or from decreased
stability of uPA mRNA. The observed down-regulation of uPA
production contradicts previous work which failed to reveal
changes in renal uPA production in LPS-injected rats [37]. This
difference may relate to the lower LPS doses used (about 10 sg
per animal) which are not considered to mimic the septic shock
but to cause a polyclonal B cell activation [38]. LPS also
modified tPA mRNA levels, which increased in glomeruli. The
increase in glomerular tPA mRNA was not accompanied by a
marked increase in tPA-mediated proteolytic activity of the
glomeruli. This apparent discrepancy could result from trans-
lational control, as shown in murine oocytes [10], or reflect the
local presence of specific inhibitors in glomerular cells. The
latter possibility is supported by the striking increase in the
amount of PAI-l mRNA that was observed diffusely in all
regions of the kidneys of LPS-injected mice, with discrete foci
of higher abundance in the cortex suggestive of a glomerular
localization. The rapid and major induction of PAl-i mRNA by
LPS is in accord with previous work performed on mice and
rats, which has shown the accumulation of PAl-i mRNA and
protein in kidney endothelial cells following LPS injection [39,
40]. In contrast to PAl-i, PAI-2 mRNA was undetectable in
normal kidneys and after LPS injection, suggesting that it plays
no role in the control of the PAiPAI system in the kidney at the
time of endotoxemia.
We have previously suggested [6] that uPA, produced by
tubular epithelial cells and secreted in urine, plays a role in the
maintenance of tubular patency and fluidity. Two LPS injec-
tions induced morphologically identifiable lesions in renal tu-
bules which consisted of tubular dilatations and epithelial cell
flattening. These alterations suggest that obstructive processes
take place in tubular structures following chronic LPS admin-
istration, which could result from intraluminal protein deposi-
tion and/or precipitation. Since LPS injections dramatically
reduce the production of uPA in the excretory compartment, it
is tempting to speculate that decreased uPA-catalyzed extracel-
lular proteolysis might contribute to tubular plugging and
thereby to the renal damages caused by septicemia. As biolog-
ical indices of renal function in LPS-injected animals point
initially towards prerenal failure, we cannot exclude that the
abolition of uPA production is an indirect effect of hypotension
and ensuing ischemia. Indeed, due to their high metabolic rate,
tubular epithelial cells are known to suffer rapidly from hypox-
emia induced by ischemia [41].
LPS-induced changes in the kidney PA/plasmin system may
also contribute to some of the intravascular repercussions of
septicemia. Alterations in fibrinolysis are known to occur
during septicemia [42, 43] and endothelial cells are recognized
targets of LPS [44-48]. In our model, LPS was found to induce
an up-regulation of tPA mRNA expression in glomerular cells,
an increase which was not associated with increased tPA-
mediated catalytic activity. As discussed above, this apparent
discrepancy is likely to reflect the concomitant and dramatic
up-regulation of PAl-i mRNA expression throughout the kid-
ney, most likely in endothelial cells [49]. Intravascular overpro-
duction of this antiprotease could contribute to the hypercoag-
ulable state induced by LPS, by decreasing fibrinolysis and
thereby promoting fibrin deposition.
In conclusion, by showing that LPS exerts major effects on
the renal PA/plasmin system, our results demonstrate that the
extracellular proteolytic balance is disturbed during pathologi-
cal processes, The study of such pathological conditions should
help gain further insights into the function of PA-catalyzed
extracellular proteolysis and into the pathogenic mechanisms of
kidney disorders.
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